ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07875
-0,01%
Bitcoin
60.894,26
0,16%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) News

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KZIA
DatumZeitQuelleÜberschriftSymbolFirma
01/05/202414h45PR Newswire (US)KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSNASDAQ:KZIAKazia Therapeutics Ltd
21/03/202413h52PR Newswire (US)Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesNASDAQ:KZIAKazia Therapeutics Ltd
13/03/202413h00PR Newswire (US)Kazia announces presentation of new data at AACR Annual MeetingNASDAQ:KZIAKazia Therapeutics Ltd
21/02/202422h19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
21/02/202415h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
21/02/202413h30PR Newswire (US)Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointNASDAQ:KZIAKazia Therapeutics Ltd
14/02/202421h41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
13/02/202400h35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KZIAKazia Therapeutics Ltd
06/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
05/02/202422h19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
18/01/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
18/01/202413h30PR Newswire (US)KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTSNASDAQ:KZIAKazia Therapeutics Ltd
12/01/202422h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
26/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
15/12/202323h26Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
15/12/202322h49Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
06/12/202314h31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
06/12/202300h02PR Newswire (US)Kazia Therapeutics Announces Closing of $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
04/12/202322h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
01/12/202314h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
01/12/202314h00PR Newswire (US)Kazia Therapeutics Announces $2 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
29/11/202322h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
29/11/202322h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
29/11/202313h01PR Newswire (US)KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGYNASDAQ:KZIAKazia Therapeutics Ltd
21/11/202313h30PR Newswire (US)KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
20/11/202322h39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
20/11/202322h30PR Newswire (US)KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATIONNASDAQ:KZIAKazia Therapeutics Ltd
15/11/202315h13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
15/11/202314h30PR Newswire (US)KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETINGNASDAQ:KZIAKazia Therapeutics Ltd
10/11/202313h01PR Newswire (US)KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMANASDAQ:KZIAKazia Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:KZIA

Kürzlich von Ihnen besucht

TG
CBK
Commerzbank
DBI
DAX
DAX
USOTC
BNPQY
BNP Paribas (QX)
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
COIN
BTCUSD
Bitcoin
TG
DTE
Deutsche Telekom
TG
RHM
Rheinmetall
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
DBI
TDXP
Tec DAX
NASDAQ
TSLA
Tesla
NYSE
NKE
Nike
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten